LINAGLIPTIN | A208335 | SUNSHINE LAKE PHARMA CO LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
BOEHRINGER INGELHEIM PHARMACEUTICALS INC. et al v. HEC PHARM CO., LTD. et al 6 patentsANDA 208335, 208336linagliptin; linagliptin and metformin hydrochloride | D.N.J. | 2015-08-04 | Terminated 2021-03-03 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Foley & Lardner LLP FDA-2017-P-2674 · 7 docket documents Foley & Lardner LLP filed this citizen petition under 21 CFR 10.30, 314.93, and Section 505(j)(2)(C) of the FD&C Act requesting that the FDA permit the filing of an ANDA for Empagliflozin and Linagliptin Capsules in 10 mg/5 mg and 25 mg/5 mg strengths, which would differ from the reference product G | Other | 2017-04-28 | Withdrawn | Foley & Lardner LLP |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.